Cargando…
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2
The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic l...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479519/ https://www.ncbi.nlm.nih.gov/pubmed/30986908 http://dx.doi.org/10.3390/molecules24071274 |
_version_ | 1783413363889405952 |
---|---|
author | Hamdy, Rania Elseginy, Samia A. Ziedan, Noha I. Jones, Arwyn T. Westwell, Andrew D. |
author_facet | Hamdy, Rania Elseginy, Samia A. Ziedan, Noha I. Jones, Arwyn T. Westwell, Andrew D. |
author_sort | Hamdy, Rania |
collection | PubMed |
description | The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukaemia. In this work we extend our previous studies on the discovery of indole-based heterocycles as Bcl-2 inhibitors, to the identification of quinolin-4-yl based oxadiazole and triazole analogues. Target compounds were readily synthesized via a common aryl-substituted quinolin-4-carbonyl-N-arylhydrazine-1-carbothioamide (5a–b) intermediate, through simple variation of the basic cyclisation conditions. Some of the quinoline-based oxadiazole analogues (e.g. compound 6i) were found to exhibit sub-micromolar anti-proliferative activity in Bcl-2-expressing cancer cell lines, and sub-micromolar IC(50) activity within a Bcl2-Bim peptide ELISA assay. The Bcl-2 targeted anticancer activity of 6i was further rationalised via computational molecular modelling, offering possibilities to extend this work into the design of further potent and selective Bcl-2 inhibitory heteroaromatics with therapeutic potential. |
format | Online Article Text |
id | pubmed-6479519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64795192019-04-30 New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 Hamdy, Rania Elseginy, Samia A. Ziedan, Noha I. Jones, Arwyn T. Westwell, Andrew D. Molecules Article The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukaemia. In this work we extend our previous studies on the discovery of indole-based heterocycles as Bcl-2 inhibitors, to the identification of quinolin-4-yl based oxadiazole and triazole analogues. Target compounds were readily synthesized via a common aryl-substituted quinolin-4-carbonyl-N-arylhydrazine-1-carbothioamide (5a–b) intermediate, through simple variation of the basic cyclisation conditions. Some of the quinoline-based oxadiazole analogues (e.g. compound 6i) were found to exhibit sub-micromolar anti-proliferative activity in Bcl-2-expressing cancer cell lines, and sub-micromolar IC(50) activity within a Bcl2-Bim peptide ELISA assay. The Bcl-2 targeted anticancer activity of 6i was further rationalised via computational molecular modelling, offering possibilities to extend this work into the design of further potent and selective Bcl-2 inhibitory heteroaromatics with therapeutic potential. MDPI 2019-04-02 /pmc/articles/PMC6479519/ /pubmed/30986908 http://dx.doi.org/10.3390/molecules24071274 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hamdy, Rania Elseginy, Samia A. Ziedan, Noha I. Jones, Arwyn T. Westwell, Andrew D. New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title_full | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title_fullStr | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title_full_unstemmed | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title_short | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2 |
title_sort | new quinoline-based heterocycles as anticancer agents targeting bcl-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479519/ https://www.ncbi.nlm.nih.gov/pubmed/30986908 http://dx.doi.org/10.3390/molecules24071274 |
work_keys_str_mv | AT hamdyrania newquinolinebasedheterocyclesasanticanceragentstargetingbcl2 AT elseginysamiaa newquinolinebasedheterocyclesasanticanceragentstargetingbcl2 AT ziedannohai newquinolinebasedheterocyclesasanticanceragentstargetingbcl2 AT jonesarwynt newquinolinebasedheterocyclesasanticanceragentstargetingbcl2 AT westwellandrewd newquinolinebasedheterocyclesasanticanceragentstargetingbcl2 |